Nuvation Bio Inc. · NYSE:NUVB
Nuvation Bio — Technical Presentation (May 2025)
10 slides from Nuvation Bio's technical presentation, May 7, 2025
Slide 1: Taletrectinib vs Crizotinib in ROS1-Positive NSCLC: A Matching-Adjusted Indirect Comparison
TALETRECTINIB VS CRIZOTINIB IN ROS1-POSITIVE NON-SMALL CELL LUNG CANCER: A MATCHING- ADJUSTED INDIRECT COMPARISON Misako Nagasaka,1 Geoffrey Liu,2 Nathan A. Pennell,3 Maurice Pérol,4 Wenfeng Chen,5 Lyudmila Bazhenova,6 Caicun Zhou7 1University of California Irvine School of Medicine and Chao Family
Slide 2: Disclosures
MAIC: Taletrectinib vs Crizotinib in ROS1+ TKI-Naive Patients DISCLOSURES Misako Nagasaka: Advisory Board: AstraZeneca, Daiichi Sankyo, Takeda, Novartis, EMD Serono, Pfizer, Lilly, Regeneron, Genentech; Consultancy: Caris Life Sciences (virtual tumor board); Speaker: Blueprint Medicines, Janssen, Mi
Slide 3: MAIC: Taletrectinib vs Crizotinib in TKI-Naive Patients With ROS1+ NSCLC
MAIC: Taletrectinib vs Crizotinib in TKI-Naive Patients With ROS1+ NSCLC • For patients with ROS1-positive (ROS1+) NSCLC, ROS1 tyrosine Taletrectinib kinase inhibitors (TKIs) are the current standard of care1 – However, most patients progress within 2 years due to acquired resistance mutations (ie,
Slide 4: MAIC: Taletrectinib vs Crizotinib in ROS1+ TKI-Naive NSCLC
MAIC: Taletrectinib vs Crizotinib in ROS1+ TKI-Naive NSCLC • Evaluated endpoints included objective response rate (ORR), progression-free TRUST I survival (PFS), overall (NCT04395677)1 PROFILE 10014 survival (OS), and grade 3 Crizotinib treatment-related adverse Matching-Adjusted Indirect Treatment
Slide 5: Baseline Comparison in ROS1+ TKI-Naive NSCLC
MAIC Taletrectinib vs Crizotinib: Baseline Comparison in ROS1+ TKI-Naive NSCLC TKI-naive populations were well balanced on measured covariates, and the effective sample size for taletrectinib was 51 Taletrectinib before adjustment Taletrectinib after adjustment Crizotinib Variables (N=160), n (%) (N
Slide 6: ORR in ROS1+ TKI-Naive NSCLC
MAIC Taletrectinib vs Crizotinib: ORR in ROS1+ TKI-Naive NSCLC After adjustment, ORR for taletrectinib was approximately 20% higher vs crizotinib Taletrectinib Taletrectinib Crizotinib (N=53) before adjustment (N=160) after adjustment (N=51) 1.9% 0.2% 3.1% 5.0% 4.7% 6.5% 3.8% 4.9% 5.7% 11.3% 6.3% CR
Slide 7: Progression-Free Survival and Overall Survival
MAIC Taletrectinib vs Crizotinib: Progression-Free Survival and Overall Survival The adjusted HRs for PFS and OS indicated a statistically significant 52% reduction in the risk of disease progression or death and a 66% reduction in the risk of death with taletrectinib vs crizotinib 1.0 1.0 Unadjuste
Slide 8: Safety
MAIC Taletrectinib vs Crizotinib: Safety in ROS1+ TKI-Naive Patients Taletrectinib before adjustment Taletrectinib after adjustment Crizotinib (N=160) (N=51) (N=53) Any grade Grade 3 Any grade Grade 3 Any grade Grade 3 The incidence of n (%) n (%) n (%) n (%) n (%) n (%) Any TRAE 159 (99) 62 (39) 51
Slide 9: Conclusions
MAIC: Taletrectinib vs Crizotinib in ROS1+ TKI-Naive Patients Conclusions • In this cross-trial MAIC analysis, taletrectinib demonstrated significantly improved outcomes compared with crizotinib in TKI-naive patients with ROS1+ NSCLC – Higher ORR was observed – Statistically significant 52% reductio
Slide 10: Acknowledgments
MAIC: Taletrectinib vs Crizotinib in ROS1+ TKI-Naive Patients Acknowledgments • We would like to thank all patients who participated in this study, the study investigators, and their staff • This study was sponsored by Nuvation Bio, Inc. Writing support was provided by Tulika Bhushan Bahukhandi, RPh